Vancouver, British Columbia, Canada, December 19, 2019 – Global Cannabis Applications Corp. (“GCAC” or the “Company”) (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading developer of innovative data and AI technologies for the medical cannabis industry, announced that it has filed a provisional method and composition patent application (Serial No. 62/950,158) with the U.S. Patent and Trademark Office (USPTO) for the System of Processing and Tracking Cannabis Products and Associated Method Using Blockchain. No assurance can be given as to whether or when a registered patent may be granted by the USPTO in the future.
Further Details: Patent Application for System of Processing and Tracking Cannabis Products and Associated Method Using Blockchain
A system and method of processing and tracking cannabis products includes a plurality of unique identifiers for a cannabis product, each associated with cannabis data that includes;
- data regarding the genetic profile of the seed used for the cannabis product
- data regarding the plant growth conditions of the crop used for the cannabis product
- data regarding the manufacture of the cannabis product
- data regarding the measurements of the quality and quantity of desired and undesired components in the cannabis product
- data regarding feedback from an end-user of the cannabis product.
The unique identifiers and cannabis data are stored in a plurality of data blocks of a blockchain, which are accessed by a cannabis processing server and processed to determine an end user treatment. This Patent Application was first filed in the USPTO to create a priority date, and allow for future filings in other selected jurisdictions, as appropriate, including Canada, Israel and the European Union.
GCAC’s Brad Moore, said “As regulators and the medical community demand trustworthy information about cannabis as a product and impact on users, GCAC’s unique processes and technology for storing cannabis data on the blockchain speaks directly to solving that problem. This patent application speaks specifically on how the company accomplishes this and utilizes its award-winning AI solution. It is the first of many related patent applications to be filed from the company as we continue to build trust and confidence in the cannabis industry and with our shareholders.”
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
To schedule an interview, please contact:
Chief Executive Officer
For more information, please contact:
Corporate Communications United States
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.